DK1233753T3 - Composition and method for treating otitis media - Google Patents
Composition and method for treating otitis media Download PDFInfo
- Publication number
- DK1233753T3 DK1233753T3 DK00959479.7T DK00959479T DK1233753T3 DK 1233753 T3 DK1233753 T3 DK 1233753T3 DK 00959479 T DK00959479 T DK 00959479T DK 1233753 T3 DK1233753 T3 DK 1233753T3
- Authority
- DK
- Denmark
- Prior art keywords
- mixture
- lipid
- lumen
- eustachian tube
- agents
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 88
- 206010033078 Otitis media Diseases 0.000 title claims abstract description 30
- 238000000034 method Methods 0.000 title abstract description 28
- 210000002388 eustachian tube Anatomy 0.000 claims abstract description 91
- 150000002632 lipids Chemical class 0.000 claims abstract description 89
- 210000000959 ear middle Anatomy 0.000 claims abstract description 64
- 239000004094 surface-active agent Substances 0.000 claims abstract description 64
- 239000003380 propellant Substances 0.000 claims abstract description 63
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 45
- 230000007480 spreading Effects 0.000 claims abstract description 41
- 238000003892 spreading Methods 0.000 claims abstract description 41
- 239000013543 active substance Substances 0.000 claims abstract description 37
- 239000013078 crystal Substances 0.000 claims abstract description 37
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims abstract description 21
- 230000001965 increasing effect Effects 0.000 claims abstract description 18
- 239000000843 powder Substances 0.000 claims abstract description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 7
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 75
- 239000003814 drug Substances 0.000 claims description 51
- BBJQPKLGPMQWBU-UHFFFAOYSA-N Palmitinsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCCCCCCCCC)C2 BBJQPKLGPMQWBU-UHFFFAOYSA-N 0.000 claims description 50
- BBJQPKLGPMQWBU-JADYGXMDSA-N cholesteryl palmitate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCC)C1 BBJQPKLGPMQWBU-JADYGXMDSA-N 0.000 claims description 50
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 32
- 239000007788 liquid Substances 0.000 claims description 29
- 210000001519 tissue Anatomy 0.000 claims description 23
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 19
- 239000012530 fluid Substances 0.000 claims description 17
- 229960003276 erythromycin Drugs 0.000 claims description 16
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical group C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 15
- 229960002537 betamethasone Drugs 0.000 claims description 14
- 229940124597 therapeutic agent Drugs 0.000 claims description 14
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical group CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims description 13
- -1 cholesteryl ester Chemical class 0.000 claims description 12
- 229960001802 phenylephrine Drugs 0.000 claims description 11
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 10
- 239000001569 carbon dioxide Substances 0.000 claims description 10
- 210000001989 nasopharynx Anatomy 0.000 claims description 10
- 239000003242 anti bacterial agent Substances 0.000 claims description 8
- 229940088710 antibiotic agent Drugs 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 6
- 230000003115 biocidal effect Effects 0.000 claims description 6
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims description 6
- 239000006185 dispersion Substances 0.000 claims description 6
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 5
- 229960003022 amoxicillin Drugs 0.000 claims description 5
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 5
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 5
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 4
- QJVHTELASVOWBE-AGNWQMPPSA-N (2s,5r,6r)-6-[[(2r)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2r,3z,5r)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 QJVHTELASVOWBE-AGNWQMPPSA-N 0.000 claims description 3
- RJECHNNFRHZQKU-UHFFFAOYSA-N Oelsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCCCCCCCC)C2 RJECHNNFRHZQKU-UHFFFAOYSA-N 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- XHRPOTDGOASDJS-UHFFFAOYSA-N cholesterol n-octadecanoate Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCCCCCCCCCCC)C2 XHRPOTDGOASDJS-UHFFFAOYSA-N 0.000 claims description 3
- RJECHNNFRHZQKU-RMUVNZEASA-N cholesteryl oleate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C1 RJECHNNFRHZQKU-RMUVNZEASA-N 0.000 claims description 3
- XHRPOTDGOASDJS-XNTGVSEISA-N cholesteryl stearate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)C1 XHRPOTDGOASDJS-XNTGVSEISA-N 0.000 claims description 3
- 229960001102 betamethasone dipropionate Drugs 0.000 claims description 2
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 claims description 2
- 239000002270 dispersing agent Substances 0.000 claims 6
- 210000000981 epithelium Anatomy 0.000 claims 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 abstract description 20
- 102000004169 proteins and genes Human genes 0.000 abstract description 8
- 108090000623 proteins and genes Proteins 0.000 abstract description 8
- 150000001720 carbohydrates Chemical class 0.000 abstract description 5
- 235000014633 carbohydrates Nutrition 0.000 abstract description 5
- 230000002708 enhancing effect Effects 0.000 abstract description 5
- 230000003247 decreasing effect Effects 0.000 abstract description 4
- 239000000443 aerosol Substances 0.000 abstract description 3
- 239000002245 particle Substances 0.000 description 18
- 208000005923 otitis media with effusion Diseases 0.000 description 15
- 230000006870 function Effects 0.000 description 13
- 210000004072 lung Anatomy 0.000 description 13
- 230000028327 secretion Effects 0.000 description 13
- 230000007423 decrease Effects 0.000 description 11
- 239000000463 material Substances 0.000 description 10
- 210000003454 tympanic membrane Anatomy 0.000 description 9
- 238000012377 drug delivery Methods 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 6
- 238000004891 communication Methods 0.000 description 6
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 6
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000003484 anatomy Anatomy 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 5
- 229940029284 trichlorofluoromethane Drugs 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 208000022760 infectious otitis media Diseases 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 229940098164 augmentin Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 239000006199 nebulizer Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000015227 regulation of liquid surface tension Effects 0.000 description 3
- 230000009747 swallowing Effects 0.000 description 3
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000699684 Meriones unguiculatus Species 0.000 description 2
- 201000006435 acute transudative otitis media Diseases 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000000850 decongestant Substances 0.000 description 2
- 229940124581 decongestants Drugs 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000002430 laser surgery Methods 0.000 description 2
- 239000003580 lung surfactant Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940071648 metered dose inhaler Drugs 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- 238000002578 otoscopy Methods 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000011369 resultant mixture Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 2
- 238000009827 uniform distribution Methods 0.000 description 2
- NHKOTKKHHYKARN-NDAAPVSOSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;3-[(1r)-1-hydroxy-2-(methylamino)ethyl]phenol Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CNC[C@H](O)C1=CC=CC(O)=C1 NHKOTKKHHYKARN-NDAAPVSOSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 206010015543 Eustachian tube dysfunction Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960004311 betamethasone valerate Drugs 0.000 description 1
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 229960003479 colfosceril palmitate Drugs 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 description 1
- 230000009189 diving Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000001595 mastoid Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229960003680 phenylephrine bitartrate Drugs 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940063649 survanta Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960001947 tripalmitin Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/450,884 US6156294A (en) | 1999-11-28 | 1999-11-28 | Composition and method for treatment of otitis media |
| PCT/US2000/023540 WO2001037806A1 (en) | 1999-11-28 | 2000-08-28 | Composition and method for treatment of otitis media |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1233753T3 true DK1233753T3 (en) | 2018-05-22 |
Family
ID=23789905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK00959479.7T DK1233753T3 (en) | 1999-11-28 | 2000-08-28 | Composition and method for treating otitis media |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US6156294A (enExample) |
| EP (1) | EP1233753B1 (enExample) |
| JP (1) | JP2003514842A (enExample) |
| AU (1) | AU776647B2 (enExample) |
| CA (1) | CA2392367C (enExample) |
| DK (1) | DK1233753T3 (enExample) |
| ES (1) | ES2663082T3 (enExample) |
| MX (1) | MXPA02005258A (enExample) |
| WO (1) | WO2001037806A1 (enExample) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7064132B2 (en) | 1999-11-28 | 2006-06-20 | Scientific Development And Research, Inc. | Composition and method for treatment of otitis external |
| US6645467B2 (en) | 1999-11-28 | 2003-11-11 | Scientific Development And Research, Inc. | Composition and method for decreasing upper respiratory airway resistance |
| US6156294A (en) * | 1999-11-28 | 2000-12-05 | Scientific Development And Research, Inc. | Composition and method for treatment of otitis media |
| US6676930B2 (en) * | 1999-11-28 | 2004-01-13 | Scientific Development And Research, Inc. | Composition and method for treatment of otitis media |
| NZ523693A (en) * | 2000-07-10 | 2004-08-27 | Chiron Corp | Macrolide formulations for inhalation and methods of treatment of endobronchial infections |
| US6599441B1 (en) * | 2000-07-18 | 2003-07-29 | Emerald Biostructures, Inc. | Crystallization solutions |
| FR2812545B1 (fr) * | 2000-08-03 | 2003-03-28 | Air Liquide Sante Int | Aerosol medicamenteux inhalable dans le traitement ou la prevention de la douceur |
| DE10105592A1 (de) | 2001-02-06 | 2002-08-08 | Achim Goepferich | Platzhalter zur Arzneistofffreigabe in der Stirnhöhle |
| US20040022740A1 (en) * | 2001-07-10 | 2004-02-05 | Baker William R. | Macrolide formulations for inhalation and methods of treatment of endobronchial infections |
| TWI324934B (en) * | 2001-08-28 | 2010-05-21 | Schering Corp | Pharmaceutical compositions for the treatment of asthma |
| US8317816B2 (en) | 2002-09-30 | 2012-11-27 | Acclarent, Inc. | Balloon catheters and methods for treating paranasal sinuses |
| JP2006510657A (ja) * | 2002-12-06 | 2006-03-30 | アライバ ファーマシューティカルズ，インコーポレイティド | 中耳炎の処置のための方法および組成物 |
| DK1638524T3 (da) * | 2003-07-02 | 2010-12-20 | Swimseal Internat Pty Ltd | Sammensætning og fremgangsmåde til behandling af vandrelaterede øreproblemer |
| US8030362B2 (en) * | 2003-12-12 | 2011-10-04 | Otic Pharma Ltd. | Compositions for treatment of ear disorders and methods of use thereof |
| US8940321B2 (en) | 2003-12-12 | 2015-01-27 | Otic Pharma Ltd. | Compositions for treatment of ear disorders and methods of use thereof |
| WO2005058879A1 (ja) * | 2003-12-17 | 2005-06-30 | Kansai Medical University | 滲出性中耳炎の予防および／または治療剤 |
| TW200600989A (en) * | 2004-04-15 | 2006-01-01 | Graco Minnesota Inc | Automatic dose size selection for multi-component fluid proportioners |
| US8894614B2 (en) | 2004-04-21 | 2014-11-25 | Acclarent, Inc. | Devices, systems and methods useable for treating frontal sinusitis |
| US8747389B2 (en) | 2004-04-21 | 2014-06-10 | Acclarent, Inc. | Systems for treating disorders of the ear, nose and throat |
| US7419497B2 (en) | 2004-04-21 | 2008-09-02 | Acclarent, Inc. | Methods for treating ethmoid disease |
| US20070208252A1 (en) | 2004-04-21 | 2007-09-06 | Acclarent, Inc. | Systems and methods for performing image guided procedures within the ear, nose, throat and paranasal sinuses |
| US8702626B1 (en) | 2004-04-21 | 2014-04-22 | Acclarent, Inc. | Guidewires for performing image guided procedures |
| US20070167682A1 (en) | 2004-04-21 | 2007-07-19 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
| US8764729B2 (en) | 2004-04-21 | 2014-07-01 | Acclarent, Inc. | Frontal sinus spacer |
| US8864787B2 (en) | 2004-04-21 | 2014-10-21 | Acclarent, Inc. | Ethmoidotomy system and implantable spacer devices having therapeutic substance delivery capability for treatment of paranasal sinusitis |
| US9351750B2 (en) | 2004-04-21 | 2016-05-31 | Acclarent, Inc. | Devices and methods for treating maxillary sinus disease |
| US20060004323A1 (en) | 2004-04-21 | 2006-01-05 | Exploramed Nc1, Inc. | Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures |
| US7559925B2 (en) | 2006-09-15 | 2009-07-14 | Acclarent Inc. | Methods and devices for facilitating visualization in a surgical environment |
| US7410480B2 (en) | 2004-04-21 | 2008-08-12 | Acclarent, Inc. | Devices and methods for delivering therapeutic substances for the treatment of sinusitis and other disorders |
| US20190314620A1 (en) | 2004-04-21 | 2019-10-17 | Acclarent, Inc. | Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures |
| US7361168B2 (en) | 2004-04-21 | 2008-04-22 | Acclarent, Inc. | Implantable device and methods for delivering drugs and other substances to treat sinusitis and other disorders |
| US7462175B2 (en) | 2004-04-21 | 2008-12-09 | Acclarent, Inc. | Devices, systems and methods for treating disorders of the ear, nose and throat |
| US9101384B2 (en) | 2004-04-21 | 2015-08-11 | Acclarent, Inc. | Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, Nose and/or throat |
| US8146400B2 (en) | 2004-04-21 | 2012-04-03 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
| US9399121B2 (en) | 2004-04-21 | 2016-07-26 | Acclarent, Inc. | Systems and methods for transnasal dilation of passageways in the ear, nose or throat |
| US9089258B2 (en) | 2004-04-21 | 2015-07-28 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
| US8932276B1 (en) | 2004-04-21 | 2015-01-13 | Acclarent, Inc. | Shapeable guide catheters and related methods |
| US20060063973A1 (en) | 2004-04-21 | 2006-03-23 | Acclarent, Inc. | Methods and apparatus for treating disorders of the ear, nose and throat |
| US7654997B2 (en) | 2004-04-21 | 2010-02-02 | Acclarent, Inc. | Devices, systems and methods for diagnosing and treating sinusitus and other disorders of the ears, nose and/or throat |
| US7803150B2 (en) | 2004-04-21 | 2010-09-28 | Acclarent, Inc. | Devices, systems and methods useable for treating sinusitis |
| US10188413B1 (en) | 2004-04-21 | 2019-01-29 | Acclarent, Inc. | Deflectable guide catheters and related methods |
| US9554691B2 (en) | 2004-04-21 | 2017-01-31 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
| CA2567334A1 (en) * | 2004-05-20 | 2005-12-08 | Discovery Laboratories, Inc. | Methods , systems and devices for noninvasive pulmonary delivery |
| US8337481B2 (en) | 2005-01-25 | 2012-12-25 | Patrick Slater | Method for treating otitis externa |
| US7981104B2 (en) * | 2005-01-25 | 2011-07-19 | Patrick Slater | Method for treating otitis externa |
| JP2008533048A (ja) * | 2005-03-10 | 2008-08-21 | スリーエム イノベイティブ プロパティズ カンパニー | 耳の感染症の治療方法 |
| US8028697B2 (en) | 2005-04-28 | 2011-10-04 | Trudell Medical International | Ventilator circuit and method for the use thereof |
| US8951225B2 (en) | 2005-06-10 | 2015-02-10 | Acclarent, Inc. | Catheters with non-removable guide members useable for treatment of sinusitis |
| US8114113B2 (en) | 2005-09-23 | 2012-02-14 | Acclarent, Inc. | Multi-conduit balloon catheter |
| US20070173463A1 (en) * | 2006-01-20 | 2007-07-26 | Brechtelsbauer Paul B | Method and composition for treating otitis media |
| WO2007100790A2 (en) * | 2006-02-27 | 2007-09-07 | Ahm Technologies, Inc. | Eustachian tube device and method |
| US7993675B2 (en) | 2006-05-10 | 2011-08-09 | Medtronic Xomed, Inc. | Solvating system and sealant for medical use in the sinuses and nasal passages |
| US7976873B2 (en) | 2006-05-10 | 2011-07-12 | Medtronic Xomed, Inc. | Extracellular polysaccharide solvating system for treatment of bacterial ear conditions |
| US7959943B2 (en) | 2006-05-10 | 2011-06-14 | Medtronics Xomed, Inc. | Solvating system and sealant for medical use in the middle or inner ear |
| US20070264296A1 (en) | 2006-05-10 | 2007-11-15 | Myntti Matthew F | Biofilm extracellular polysachharide solvating system |
| US8190389B2 (en) | 2006-05-17 | 2012-05-29 | Acclarent, Inc. | Adapter for attaching electromagnetic image guidance components to a medical device |
| US9820688B2 (en) | 2006-09-15 | 2017-11-21 | Acclarent, Inc. | Sinus illumination lightwire device |
| US8439687B1 (en) | 2006-12-29 | 2013-05-14 | Acclarent, Inc. | Apparatus and method for simulated insertion and positioning of guidewares and other interventional devices |
| US8088095B2 (en) | 2007-02-08 | 2012-01-03 | Medtronic Xomed, Inc. | Polymeric sealant for medical use |
| US8118757B2 (en) | 2007-04-30 | 2012-02-21 | Acclarent, Inc. | Methods and devices for ostium measurement |
| US8485199B2 (en) | 2007-05-08 | 2013-07-16 | Acclarent, Inc. | Methods and devices for protecting nasal turbinate during surgery |
| US10206821B2 (en) | 2007-12-20 | 2019-02-19 | Acclarent, Inc. | Eustachian tube dilation balloon with ventilation path |
| US20100198191A1 (en) | 2007-12-20 | 2010-08-05 | Acclarent, Inc. | Method and system for treating target tissue within the eustachian tube |
| US8182432B2 (en) | 2008-03-10 | 2012-05-22 | Acclarent, Inc. | Corewire design and construction for medical devices |
| SI2265309T1 (sl) | 2008-03-17 | 2016-04-29 | Discovery Laboratories, Inc. | Adapter za cevje ventilatorja in sistem za proksimalno dovajanje aerosola |
| BRPI0912126A2 (pt) * | 2008-05-27 | 2015-11-03 | Univ Melbourne | método de tratamento de mamíferos com disfunções na trompa de eustáquio |
| US8784790B2 (en) | 2008-06-12 | 2014-07-22 | Medtronic Xomed, Inc. | Method for treating chronic wounds with an extracellular polymeric substance solvating system |
| ES2700863T3 (es) | 2008-07-30 | 2019-02-19 | Acclarent Inc | Dispositivos de localización del ostium paranasal |
| EP2323724A1 (en) | 2008-09-18 | 2011-05-25 | Acclarent, Inc. | Methods and apparatus for treating disorders of the ear nose and throat |
| US20100086576A1 (en) * | 2008-10-06 | 2010-04-08 | Myntti Matthew F | Antimicrobial composition and methods of making and using same |
| US8596265B2 (en) | 2008-10-22 | 2013-12-03 | Trudell Medical International | Modular aerosol delivery system |
| US20100241155A1 (en) | 2009-03-20 | 2010-09-23 | Acclarent, Inc. | Guide system with suction |
| US8435290B2 (en) | 2009-03-31 | 2013-05-07 | Acclarent, Inc. | System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx |
| US7978742B1 (en) | 2010-03-24 | 2011-07-12 | Corning Incorporated | Methods for operating diode lasers |
| US9155492B2 (en) | 2010-09-24 | 2015-10-13 | Acclarent, Inc. | Sinus illumination lightwire device |
| WO2013040352A1 (en) | 2011-09-15 | 2013-03-21 | Yoseph Yaacobi | Systems and methods for treating ear disorders |
| US10653133B2 (en) | 2011-05-10 | 2020-05-19 | Next Science IP Holdings Pty Ltd | Antimicrobial solid and methods of making and using same |
| US8758836B2 (en) * | 2011-09-09 | 2014-06-24 | Nina S. YOSHPE | Method and formulation for treating dry ear inflammation with cortisone |
| US9629684B2 (en) | 2013-03-15 | 2017-04-25 | Acclarent, Inc. | Apparatus and method for treatment of ethmoid sinusitis |
| US9433437B2 (en) | 2013-03-15 | 2016-09-06 | Acclarent, Inc. | Apparatus and method for treatment of ethmoid sinusitis |
| US9895311B2 (en) | 2014-09-25 | 2018-02-20 | Pharmiva Ab | Foam-forming compositions and methods for delivering an active to a body cavity |
| WO2016160967A1 (en) | 2015-03-31 | 2016-10-06 | Acclarent, Inc. | Eustachian tube dilation balloon with ventilation path |
| JP2018535277A (ja) * | 2015-11-30 | 2018-11-29 | ノヴァス・セラピューティクス・インコーポレーテッド | 耳科学的予防および処置のための組成物および方法 |
| US11795192B2 (en) | 2017-03-10 | 2023-10-24 | Lakewood Amedex, Inc. | Antimicrobial compounds, compositions, and uses thereof |
| WO2018215474A1 (en) | 2017-05-23 | 2018-11-29 | Pharmiva Ab | Foam-forming compositions for delivering an active to a body cavity |
| KR20230031370A (ko) | 2017-06-12 | 2023-03-07 | 레이크우드 아메덱스, 인크. | 비스포스포신 겔 제제 및 이의 용도 |
| US11331269B2 (en) * | 2018-09-06 | 2022-05-17 | Massachusetts Institute Of Technology | Methods and compositions targeting lung microbiota and its responding immune pathways for lung cancer treatment |
| MX2021004396A (es) | 2018-10-17 | 2021-06-04 | Lakewood Amedex Inc | Metodos y composiciones para el tratamiento de la mucositis oral. |
| EP3914323A4 (en) * | 2019-01-23 | 2022-10-05 | Alrich Partners, Inc. | METHOD FOR IMPROVING EUSTACHE POLE PERMEABILITY AND TREATMENT OF OTITIS MEDIA |
| CA3175700A1 (en) * | 2021-06-11 | 2022-12-11 | Ankh Life Sciences Limited | Lipid crystalline compositions with enhanced stability for topical delivery of active agent combinations |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0158441B2 (en) * | 1984-03-08 | 2001-04-04 | Phares Pharmaceutical Research N.V. | Liposome-forming composition |
| US5141674A (en) * | 1984-03-08 | 1992-08-25 | Phares Pharmaceutical Research N.V. | Methods of preparing pro-liposome dispersions and aerosols |
| GB8501015D0 (en) * | 1985-01-16 | 1985-02-20 | Riker Laboratories Inc | Drug |
| US5192528A (en) | 1985-05-22 | 1993-03-09 | Liposome Technology, Inc. | Corticosteroid inhalation treatment method |
| EP0223831B1 (en) * | 1985-05-22 | 1992-07-15 | Liposome Technology, Inc. | Liposome inhalation method and system |
| US4826821A (en) | 1985-06-26 | 1989-05-02 | The Regents Of The University Of California | Lung surfactant compositions |
| FR2586587B1 (fr) | 1985-08-30 | 1987-10-23 | Adir | Nouveaux surfactants artificiels, leur preparation et les compositions pharmaceutiques qui les contiennent. |
| SE462894B (sv) * | 1985-10-28 | 1990-09-17 | Biogram Ab | Mikrokapslar, foerfarande foer framstaellning daerav samt anvaendning |
| US5013720A (en) | 1986-05-06 | 1991-05-07 | Abbott Laboratories | SAP-6-Val proteins and methods |
| SE8603812D0 (sv) | 1986-09-12 | 1986-09-12 | Draco Ab | Administration of liposomes to mammals |
| CA1338736C (fr) * | 1986-12-05 | 1996-11-26 | Roger Baurain | Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation |
| IT1203873B (it) | 1987-04-08 | 1989-02-23 | Chiesi Farma Spa | Composizioni farmaceutiche che lo surfattante polmonare naturale, contengono. metodo di preparazione e |
| JP2656944B2 (ja) | 1987-04-30 | 1997-09-24 | クーパー ラボラトリーズ | タンパク質性治療剤のエアロゾール化 |
| US5260273A (en) | 1988-01-06 | 1993-11-09 | The Scripps Research Institute | Pulmonary surfactant protein and related polypeptide |
| JPH01258620A (ja) * | 1988-04-08 | 1989-10-16 | Dai Ichi Seiyaku Co Ltd | 耳疾患用局所製剤 |
| MX9203504A (es) | 1988-04-20 | 1992-07-01 | Liposome Co Inc | Complejo agente: lipido activo de alta proporcion. |
| JPH01313423A (ja) * | 1988-06-03 | 1989-12-18 | Biogal Gyogyszergyar | 耳炎用点耳薬の新規製薬組成物 |
| US4906476A (en) | 1988-12-14 | 1990-03-06 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs in lungs |
| US5134129A (en) | 1989-03-15 | 1992-07-28 | Board Of Regents, The University Of Texas System | Methods employing unique mixtures of polar and neutral lipids for surfactant replacement therapy |
| US5174988A (en) * | 1989-07-27 | 1992-12-29 | Scientific Development & Research, Inc. | Phospholipid delivery system |
| US5238920A (en) | 1989-08-22 | 1993-08-24 | Abbott Laboratories | Pulmonary surfactant protein fragments |
| US5888505A (en) | 1991-02-21 | 1999-03-30 | Eoe, Inc. | Method for selectively inhibiting the growth of microbes using a haloperoxidase-halide-peroxide system |
| EP0724386A1 (en) * | 1991-04-29 | 1996-08-07 | DI BARTOLOMEO, Joseph R. | Composition and method for treatment of patulous eustachian tube syndrome and atrophic rhinitis |
| ZA926834B (en) | 1991-09-09 | 1993-03-15 | American Cyanamid Co | Antibiotic LL-E19020 Gamma. |
| GB9120005D0 (en) | 1991-09-19 | 1991-11-06 | Wellcome Found | Method of administering phospholipid dispersions |
| ES2079994B1 (es) | 1992-10-07 | 1996-08-01 | Cusi Lab | Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica. |
| IS1796B (is) | 1993-06-24 | 2001-12-31 | Ab Astra | Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband |
| DE4323636A1 (de) | 1993-07-15 | 1995-01-19 | Hoechst Ag | Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung |
| SA95160463B1 (ar) | 1994-12-22 | 2005-10-04 | استرا أكتيبولاج | مساحيق للاستنشاق |
| WO1996025918A1 (en) | 1995-02-24 | 1996-08-29 | Nanosystems L.L.C. | Aerosols containing nanoparticle dispersions |
| WO1996027393A1 (en) | 1995-03-07 | 1996-09-12 | University Of Pittsburgh | A dry powder formulation for gene therapy |
| DZ2028A1 (fr) * | 1995-05-03 | 2002-10-23 | Smithkline Beecham Plc | Médicaments destinés au traitement d'infections bactériennes en pédiatrie. |
| ES2173287T3 (es) | 1995-06-06 | 2002-10-16 | Bayer Ag | Composiciones oticas antibacterianas no irritantes, no sensibilizantes y no ototoxicas. |
| US5843930A (en) | 1995-06-06 | 1998-12-01 | Bayer Corporation | Method of treating otitis with ciprofloxacin-hydrocortisone suspension |
| US6129934A (en) | 1995-06-07 | 2000-10-10 | Ony, Inc. | Modification of animal lung surfactant for treating respiratory disease due to lung surfactant deficiency or dysfunction |
| WO1997029738A1 (en) * | 1996-02-16 | 1997-08-21 | The Administrators Of The Tulane Educational Fund | Methods and compositions for treating eustachian tube dysfunction by inhalation |
| US6423694B1 (en) * | 1996-02-21 | 2002-07-23 | Inspire Pharmaceuticals, Inc. | Method of treating otitis media with uridine triphosphates and related compounds |
| AU2322097A (en) | 1996-03-27 | 1997-10-17 | Ortho Pharmaceutical Corporation | Lyophilized pulmonary surfactant peptide compositions |
| USRE37053E1 (en) | 1996-05-24 | 2001-02-13 | Massachusetts Institute Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5958378A (en) | 1996-07-03 | 1999-09-28 | Research Development Foundation | High dose liposomal aerosol formulations containing cyclosporin A or budesonide |
| US5954682A (en) | 1996-09-25 | 1999-09-21 | Advanced Medical Instruments | Therapeutic applicator apparatus and method |
| WO1998014189A1 (en) * | 1996-10-01 | 1998-04-09 | Smithkline Beecham Corporation | Use of mupirocin for the manufacture of a medicament for the treatment of bacterial infections associated with colonisation of the nasopharynx by pathogenic organisms |
| US6040463A (en) | 1996-10-07 | 2000-03-21 | Merck & Co., Inc. | Sordarin derivatives |
| US6143276A (en) | 1997-03-21 | 2000-11-07 | Imarx Pharmaceutical Corp. | Methods for delivering bioactive agents to regions of elevated temperatures |
| EP1005327A1 (en) | 1997-07-02 | 2000-06-07 | Sdg, Inc. | Targeted liposomal constructs for diagnostic and therapeutic uses |
| US5925334A (en) | 1997-08-27 | 1999-07-20 | Rubin; Bruce K. | Use of surface active agents to promote mucus clearance |
| US6309623B1 (en) | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
| WO1999033472A1 (en) | 1997-12-24 | 1999-07-08 | Britannia Pharmaceuticals Limited | Use of surface active agent for the manufacture of a medicament for treatment of disorders of the middle ear |
| GB9807298D0 (en) * | 1998-04-03 | 1998-06-03 | Britannia Pharmaceuticals Ltd | Medicament |
| US6200598B1 (en) | 1998-06-18 | 2001-03-13 | Duke University | Temperature-sensitive liposomal formulation |
| US6156294A (en) * | 1999-11-28 | 2000-12-05 | Scientific Development And Research, Inc. | Composition and method for treatment of otitis media |
-
1999
- 1999-11-28 US US09/450,884 patent/US6156294A/en not_active Expired - Lifetime
-
2000
- 2000-08-16 US US09/639,730 patent/US6521213B1/en not_active Expired - Lifetime
- 2000-08-16 US US09/639,682 patent/US6616913B1/en not_active Expired - Lifetime
- 2000-08-16 US US09/639,739 patent/US6572841B1/en not_active Expired - Lifetime
- 2000-08-28 DK DK00959479.7T patent/DK1233753T3/en active
- 2000-08-28 EP EP00959479.7A patent/EP1233753B1/en not_active Expired - Lifetime
- 2000-08-28 JP JP2001539421A patent/JP2003514842A/ja active Pending
- 2000-08-28 MX MXPA02005258A patent/MXPA02005258A/es active IP Right Grant
- 2000-08-28 ES ES00959479.7T patent/ES2663082T3/es not_active Expired - Lifetime
- 2000-08-28 AU AU70798/00A patent/AU776647B2/en not_active Ceased
- 2000-08-28 CA CA002392367A patent/CA2392367C/en not_active Expired - Lifetime
- 2000-08-28 WO PCT/US2000/023540 patent/WO2001037806A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001037806A1 (en) | 2001-05-31 |
| ES2663082T3 (es) | 2018-04-11 |
| AU776647B2 (en) | 2004-09-16 |
| JP2003514842A (ja) | 2003-04-22 |
| US6521213B1 (en) | 2003-02-18 |
| CA2392367A1 (en) | 2001-05-31 |
| EP1233753A4 (en) | 2009-09-23 |
| US6616913B1 (en) | 2003-09-09 |
| AU7079800A (en) | 2001-06-04 |
| EP1233753B1 (en) | 2018-02-14 |
| MXPA02005258A (es) | 2004-04-21 |
| US6156294A (en) | 2000-12-05 |
| US6572841B1 (en) | 2003-06-03 |
| CA2392367C (en) | 2009-08-04 |
| EP1233753A1 (en) | 2002-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1233753B1 (en) | Composition and method for treatment of otitis media | |
| US6676930B2 (en) | Composition and method for treatment of otitis media | |
| US5306483A (en) | Phospholipid delivery system | |
| US6544542B1 (en) | Fat emulsions for inhalational administration | |
| Khan et al. | Liposome-based carrier systems and devices used for pulmonary drug delivery | |
| CA2335900C (en) | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery | |
| EP1968538B1 (de) | Pharmazeutische zusammensetzungen mit cyclosporin | |
| JP2005511648A5 (enExample) | ||
| ES2395130T3 (es) | Método y composición para el tratamiento de rinitis | |
| EP1460967B1 (en) | Composition and method for treatment of otitis externa | |
| WO1987001586A1 (en) | Aerosol | |
| US6645467B2 (en) | Composition and method for decreasing upper respiratory airway resistance | |
| US8466134B1 (en) | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery | |
| Aydin | Aerosolisation and in-vitro deposition of an artificial lung surfactant | |
| WO2003061668A1 (en) | Use of pulmonary surfactant for the prevention of infectious diseases | |
| Hidayat | Proniosome formulations for pulmonary drug delivery | |
| HK1098960B (en) | Method and composition for treating rhinitis | |
| WO2003009873A2 (en) | Use of pulmonary surfactant as humectant |